Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 349 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Attention Control Clear all
Recruiting Not applicable Interventional

Feasibility/Acceptability of Attentional-Control Training in Survivors

NCT05528939
View directory record Official record
Conditions
Pediatric Cancer, Pediatric ALL, Pediatric Brain Tumor, Attention Difficulties, Cognitive Deficit in Attention
Interventions
EndeavorRx, Control video game
Device · Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
8 Years to 16 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 22, 2026, 1:04 AM EDT
Not listed Not applicable Interventional

Disclosure to Family

NCT02111720
View directory record Official record
Conditions
HIV Risk Reduction, Attention Control Case Management
Interventions
Maybe, Maybe Not, Comprehensive Risk Counseling and Services
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 22, 2026, 1:04 AM EDT
Not yet recruiting Phase 4 Interventional

High-concentration Capsaicin Patch for the Prevention of Paclitaxel-induced Peripheral Neuropathy

NCT07834281
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Interventions
High Concentration Capsaicin Patch (HCCP), Placebo patch
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 22, 2026, 1:04 AM EDT
Not listed Not applicable Interventional

Online Intervention for Traumatic Brain Injury Wellbeing

NCT05115656
View directory record Official record
Conditions
Traumatic Brain Injury, Attention Impaired, Emotional Regulation
Interventions
Online group 1, Online group 2
Behavioral
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 22, 2026, 1:04 AM EDT
Completed Phase 3 Interventional

A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder

NCT05257265
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Centanafadine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 22, 2026, 1:04 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Video Game Play to Alleviate Adolescent Anxiety

NCT05923944
View directory record Official record
Conditions
Anxiety, Anxiety Disorders and Symptoms
Interventions
Eco-Rescue, Bejelewed 3
Behavioral
Lead sponsor
School of Health Sciences Geneva
Other
Eligibility
11 Years to 15 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 1:04 AM EDT
Completed Not applicable Interventional Results available

Optimizing Functional Recovery of Breast Cancer Survivors

NCT03915548
View directory record Official record
Conditions
Breast Cancer Female
Interventions
The Behavioral Activation/ Problem Solving Intervention, Attention Control Condition
Behavioral
Lead sponsor
MGH Institute of Health Professions
Other
Eligibility
18 Years and older · Female only
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 22, 2026, 1:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Effects of Three Doses of the Dietary Supplement oréVida™ on Alertness, Attention and Concentration in Healthy Men and Women

NCT01143194
View directory record Official record
Conditions
Attention, Memory, Alertness
Interventions
oréVida™, Placebo
Dietary Supplement
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
35 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Oct 22, 2026, 1:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Immediate-Release Viloxazine in Adults With ADHD

NCT01107496
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
IR Viloxazine, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Bradenton, Florida • Libertyville, Illinois • Owensboro, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 22, 2026, 1:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Cognition and Control in Youths

NCT03393390
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder
Interventions
Clinical Assessment Visit, fMRI scan
Diagnostic Test · Other
Lead sponsor
University of Michigan
Other
Eligibility
6 Years to 18 Years
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 22, 2026, 1:04 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Brain Training for Substance Use Disorders

NCT06870110
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Bias Modification Biofeedback
Device
Lead sponsor
Neurotype Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 22, 2026, 1:04 AM EDT
Recruiting Not applicable Interventional

Computer - Based Treatment for Social Anxiety Disorder

NCT04663724
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Computer-Based Treatment
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 22, 2026, 1:04 AM EDT
Terminated Phase 4 Interventional Results available

Lisdexamfetamine's Effect In ADHD in the Brain and Cognition

NCT02170298
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years to 30 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 22, 2026, 1:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Genetics on Metformin Pharmacokinetics

NCT00187798
View directory record Official record
Conditions
Other Conditions That May Be A Focus of Clinical Attention
Interventions
Metformin HCl
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Oct 22, 2026, 1:04 AM EDT
Completed Phase 2 Interventional

Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00640419
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
ABT-089, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
6 Years to 12 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
13
States / cities
Little Rock, Arkansas • Bradenton, Florida • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 22, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01458340
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder, ADHD
Interventions
TD-9855, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 45 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Bradenton, Florida • Jacksonville, Florida • Maitland, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 22, 2026, 1:04 AM EDT
Completed Phase 2 Interventional Results available

PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations

NCT03609619
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
AEVI-001, Placebo
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
6 Years to 17 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Wayne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 22, 2026, 1:04 AM EDT
Terminated Early Phase 1 Interventional Results available

Amiloride Hydrochloride as an Effective Treatment for ADHD

NCT01733680
View directory record Official record
Conditions
ADHD
Interventions
amiloride, Behavioral
Drug · Behavioral
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 22, 2026, 1:04 AM EDT
Completed Phase 2Phase 3 Interventional

Dasotraline Pediatric ADHD Study

NCT02428088
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dasotraline, Placebo Comparator
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
43
States / cities
Dothan, Alabama • National City, California • Paramount, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 22, 2026, 1:04 AM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

NCT01150097
View directory record Official record
Conditions
Liver Transplant Recipient
Interventions
Tacrolimus (reduced tacrolimus), Everolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Everolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
20 Years to 75 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Lexington, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 22, 2026, 1:04 AM EDT
Recruiting Not applicable Interventional

Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease

NCT05099874
View directory record Official record
Conditions
Sickle Cell Disease, Attention Deficit, Cognitive Deficit in Attention
Interventions
EndeavorRx
Device
Lead sponsor
Children's National Research Institute
Other
Eligibility
8 Years to 16 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 22, 2026, 1:04 AM EDT
Completed Not applicable Interventional

Mindfulness-Based Blood Pressure Reduction: Stage 2a RCT

NCT03256890
View directory record Official record
Conditions
Hypertension, Prehypertension
Interventions
MB-BP Intervention, Enhanced Usual Care Control
Behavioral · Other
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 22, 2026, 1:04 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of SPD503 in Combination With Psychostimulants

NCT00734578
View directory record Official record
Conditions
ADHD
Interventions
SPD503-AM, SPD503-PM, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
61
States / cities
Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 22, 2026, 1:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multi-limb Dual-task Control in Parkinson's Disease

NCT03662009
View directory record Official record
Conditions
Parkinson Disease
Interventions
multilimb dual task
Other
Lead sponsor
A.T. Still University of Health Sciences
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 22, 2026, 1:04 AM EDT